{{Drugbox
| Verifiedfields = changed
| Watchedfields = changed
| verifiedrevid = 443732840
| IUPAC_name = (6a''R'',9''R'')-''N''-((2''R'',5''S'',10a''S'',10b''S'')-5-Benzyl-10b-hydroxy-2-methyl-3,6-dioxooctahydro-2''H''-oxazolo[3,2-''a'']pyrrolo[2,1-''c'']pyrazin-2-yl)-7-methyl-4,6,6a,7,8,9-hexahydroindolo[4,3-''fg'']quinoline-9-carboxamide
| image = Ergotamine-skeletal.svg
| width = 250
| image2 = Ergotamine ball-and-stick.png
<!--Clinical data-->
| tradename = [[Cafergot|Cafergot]], Ergomar
| Drugs.com = {{drugs.com|monograph|ergomar}}
| pregnancy_US = X
| pregnancy_category =  
| legal_AU = Schedule 4
| legal_CA = Schedule VI
| legal_UK = POM
| legal_US = Rx Only; [[DEA_list_of_chemicals|DEA controlled precursor]]
| routes_of_administration = [[wikt:oral|Oral]]
<!--Pharmacokinetic data-->
| bioavailability = Intravenous: 100%,<ref name="kinetics1">{{cite journal|last=Sanders|first=SW|author2=Haering N |author3=Mosberg H |author4=Jaeger H |title=Pharmacokinetics of ergotamine in healthy volunteers following oral and rectal dosing|journal=Eur J Clin Pharmacol|date=1986|volume=30|issue=3|pages=331–4|doi=10.1007/BF00541538|pmid=3732370}}</ref> <br />Intramuscular: 47%,<ref name="kinetics2">Tfelt-Hansen P, Johnson ES. Ergotamine. In: Olesen J, Tfelt-Hansen P, Welch KM, editors. The headaches. New York: Raven Press; 1993. p. 313–22.</ref><br />Oral: <1% <ref>Ibraheem JJ, Paalzow L, Tfelt-Hansen P. Low bioavailability of ergotamine tartrate after oral and rectal administration in migraine sufferers. ''Br J Clin Pharmacol'' 1983; 16: 695–9.</ref> (Enhanced by co-administration of caffeine <ref name="kinetics1" />)
| metabolism = Hepatic <ref name="kinetics2" />
| elimination_half-life = 2 hours <ref name="kinetics2" />
| excretion = 90% biliary <ref name="kinetics2" />
<!--Identifiers-->
| CAS_number_Ref = {{cascite|correct|??}}
| CAS_number = 113-15-5
| ATC_prefix = N02
| ATC_suffix = CA02
| PubChem = 8223
| ChEBI_Ref = {{ebicite|changed|EBI}}
| ChEBI = 64318
| IUPHAR_ligand = 149
| DrugBank_Ref = {{drugbankcite|correct|drugbank}}
| DrugBank = DB00696
| ChemSpiderID_Ref = {{chemspidercite|correct|chemspider}}
| ChemSpiderID = 7930
| UNII_Ref = {{fdacite|correct|FDA}}
| UNII = PR834Q503T
| KEGG_Ref = {{keggcite|correct|kegg}}
| KEGG = D07906
| ChEMBL_Ref = {{ebicite|correct|EBI}}
| ChEMBL = 442
<!--Chemical data-->
| C=33 | H=35 | N=5 | O=5
| molecular_weight = 581.66 g/mol
| smiles = O=C3N1CCC[C@H]1[C@]2(O)O[C@](C(=O)N2[C@H]3Cc4ccccc4)(NC(=O)[C@@H]8/C=C7/c5cccc6c5c(cn6)C[C@H]7N(C)C8)C
| StdInChI_Ref = {{stdinchicite|correct|chemspider}}
| StdInChI = 1S/C33H35N5O5/c1-32(35-29(39)21-15-23-22-10-6-11-24-28(22)20(17-34-24)16-25(23)36(2)18-21)31(41)38-26(14-19-8-4-3-5-9-19)30(40)37-13-7-12-27(37)33(38,42)43-32/h3-6,8-11,15,17,21,25-27,34,42H,7,12-14,16,18H2,1-2H3,(H,35,39)/t21-,25-,26+,27+,32-,33+/m1/s1
| StdInChIKey_Ref = {{stdinchicite|correct|chemspider}}
| StdInChIKey = XCGSFFUVFURLIX-VFGNJEKYSA-N
}}
{{medical}}
'''麦角胺'''是麦角肽碱，是麦角类[[生物碱|生物碱]]的一种，它在结构与生物化学上和Ergoline密切相关。它的结构和几种[[神经递质|神经递质]]的结构相似，并且具有作为血管收缩剂的生物活性。

它用于医学上用于治疗急性[[偏头痛|偏头痛]]发作（有时与[[咖啡因|咖啡因]]共用）。麦角真菌的药物使用始于16世纪诱导[[分娩|分娩]]，但其剂量的不确定性阻止了使用。它已被用于防止产后出血（分娩后出血）。它首先在1918年被Sandoz的Arthur Stoll从麦角真菌中分离出来，1921年以商品名Gynergen销售.<ref>AJ Giannini, AE Slaby. Drugs of Abuse. Oradell, NJ, Medical Economics Books, 1989。</ref>

==副作用==
麦角胺的副作用包括[[恶心|恶心]]和[[呕吐|呕吐]]。在较高的剂量下，它可引起动脉血压升高、血管收缩（包括冠状动脉血管痉挛）和心动过缓或过速。严重的血管收缩可能引起间歇性跛行的症状。<ref>{{cite web|url=http://www.drugs.com/pro/medihaler-ergotamine.html|title=Medihaler Ergotamine|website=[[drugs.com|drugs.com]]|accessdate=2016-05-20}}</ref>
==参考文献==
{{reflist}}
==参见==
* [[麦角中毒|麦角中毒]]
* [[麦角新碱|麦角新碱]]
* {{link-en|二氢麦角胺|Dihydroergotamine}}（双氢麦角胺）
* [[D-麦角酸二乙胺|D-麦角酸二乙胺]]

{{抗偏头痛药}}
{{Serotonergics}}
[[category:抗偏头痛药物|category:抗偏头痛药物]]
[[Category:α-肾上腺素激动药|Category:α-肾上腺素激动药]]
[[category:内酰胺|category:内酰胺]]
[[Category:麦角酰胺|Category:麦角酰胺]]